Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Sweden's Q-linea Q3 sales rise; signs new US healthcare agreement

By Reuters News


Overview

  • Sweden infection diagnostics firm's Q3 net sales grew yr/yr, but contracted instrument sales declined

  • Operating loss for Q3 narrowed compared to last year

  • Company signed US healthcare agreement and Premier, Inc. framework deal, but US adoption remains slow


Outlook

  • Company expects evaluation timelines to decrease as more real-world data is generated

  • Company anticipates further deployments in Europe later this year following positive evaluations

  • Q-linea expects to announce further product and menu expansions within 6-12 months


Result Drivers

  • US MARKET CONTRACTS - Co signed new US healthcare agreement and expanded with existing IDN customer in Q3

  • GROUP PURCHASING DEAL - National framework agreement with Premier, Inc. expected to reduce contracting timelines and increase visibility

  • CONSUMABLES USAGE - US consumables usage reached highest level in Q3 after expanded menu adoption


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Loss

SEK 29.30 mln

Q3 Adjusted Free Cash Flow

-SEK 34.30 mln

Q3 EBIT

-SEK 30.60 mln


Reuters Recommended Reads

  • Oct 28 - GE Healthcare Q3 profit beats estimates on advanced imaging segment

  • Oct 28 - Sweden's Fenix Outdoor Q3 sales rise on Nordic demand, Devold portfolio addition

  • Oct 29 - Sweden's Nolato Q3 profit slips on higher input costs


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.